• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    2/22/24 8:05:56 AM ET
    $AGRX
    $APYX
    $ATPC
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AGRX alert in real time by email

    Gainers

    • Agile Therapeutics (NASDAQ:AGRX) stock rose 82.4% to $1.81 during Thursday's pre-market session. The company's market cap stands at $5.3 million.
    • Venus Concept (NASDAQ:VERO) stock rose 72.95% to $2.11. The market value of their outstanding shares is at $11.6 million.
    • Monopar Therapeutics (NASDAQ:MNPR) stock rose 71.91% to $0.98. The market value of their outstanding shares is at $14.5 million.
    • Ocular Therapeutix (NASDAQ:OCUL) shares increased by 21.27% to $9.12. The market value of their outstanding shares is at $1.0 billion.
    • Indivior (NASDAQ:INDV) shares increased by 16.74% to $20.43. The market value of their outstanding shares is at $2.7 billion. As per the press release, Q4 earnings came out today.
    • Apyx Medical (NASDAQ:APYX) shares increased by 15.3% to $2.33. The company's market cap stands at $80.6 million.

    Losers

    • Synaptogenix (NASDAQ:SNPX) shares fell 20.9% to $0.21 during Thursday's pre-market session. The market value of their outstanding shares is at $4.2 million.
    • Motus GI Hldgs (NASDAQ:MOTS) shares declined by 18.19% to $0.9. The company's market cap stands at $1.3 million.
    • Chemomab Therapeutics (NASDAQ:CMMB) shares decreased by 9.69% to $0.61. The market value of their outstanding shares is at $6.8 million.
    • Agape ATP (NASDAQ:ATPC) shares fell 8.86% to $0.32. The company's market cap stands at $24.5 million.
    • China Pharma Holding (AMEX:CPHI) stock decreased by 7.91% to $0.09. The market value of their outstanding shares is at $4.8 million.
    • Cadrenal Therapeutics (NASDAQ:CVKD) stock declined by 7.84% to $0.68. The market value of their outstanding shares is at $8.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRX
    $APYX
    $ATPC
    $CMMB

    CompanyDatePrice TargetRatingAnalyst
    Monopar Therapeutics Inc.
    $MNPR
    1/9/2026$115.00Overweight
    Morgan Stanley
    Apyx Medical Corporation
    $APYX
    12/16/2025$6.00Buy
    Roth Capital
    Apyx Medical Corporation
    $APYX
    11/14/2025Mkt Perform → Mkt Outperform
    Citizens JMP
    Monopar Therapeutics Inc.
    $MNPR
    11/14/2025Strong Buy → Outperform
    Raymond James
    Apyx Medical Corporation
    $APYX
    11/12/2025$8.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Monopar Therapeutics Inc.
    $MNPR
    11/10/2025$115.00Outperform
    Leerink Partners
    Monopar Therapeutics Inc.
    $MNPR
    10/13/2025$125.00Overweight
    Barclays
    Ocular Therapeutix Inc.
    $OCUL
    9/15/2025$21.00Buy
    Chardan Capital Markets
    More analyst ratings

    $AGRX
    $APYX
    $ATPC
    $CMMB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Barbara bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 65% to 1,963 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:51:48 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Humphreys Keith bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 15% to 5,802 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:50:38 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $APYX
    $ATPC
    $CMMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Dugel Pravin sold $166,064 worth of shares (20,056 units at $8.28), decreasing direct ownership by 0.66% to 3,013,022 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/25/26 6:20:23 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Kaiser Peter sold $23,267 worth of shares (2,810 units at $8.28), decreasing direct ownership by 1% to 269,108 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/25/26 6:19:11 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Heier Jeffrey S. sold $25,312 worth of shares (3,057 units at $8.28), decreasing direct ownership by 0.94% to 323,368 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/25/26 6:18:30 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $APYX
    $ATPC
    $CMMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Monopar Therapeutics with a new price target

    Morgan Stanley initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $115.00

    1/9/26 9:05:54 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Apyx Medical with a new price target

    Roth Capital initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $6.00

    12/16/25 8:46:26 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Apyx Medical upgraded by Citizens JMP

    Citizens JMP upgraded Apyx Medical from Mkt Perform to Mkt Outperform

    11/14/25 10:23:10 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $AGRX
    $APYX
    $ATPC
    $CMMB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026

    CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81

    2/25/26 9:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

    Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 Meeting Scheduled for March 2026 PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced encouraging results from a Phase 2 trial evaluating CAD-1005 (formerly VLX-1005) in patients with heparin-induced thrombocytopenia (HIT), a severe pro-thrombotic reaction to heparin, the most commonly used parenteral anticoagulant

    2/24/26 8:30:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Participate in March Investor Conferences

    BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in several upcoming investor conferences in March 2026. TD Cowen 46th Annual Health Care Conference:Date: Monday, March 2, 2026Fireside Chat: 9:10 – 9:40 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Boston, MA Jefferies Biotech on the Beach Summit:Date: Tuesday, March 10, 2026Location: Miami, FL Citizens Life Sciences Conference 2026:Date: Wednesday, March 11, 2026Fireside Chat: 9:00 – 9:25 AM ETPresenter: Pravin U

    2/24/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $APYX
    $ATPC
    $CMMB
    SEC Filings

    View All

    Cadrenal Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

    2/24/26 8:35:37 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Chemomab Therapeutics Ltd.

    SCHEDULE 13G/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    2/17/26 4:48:53 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.

    SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)

    2/17/26 4:37:51 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $APYX
    $ATPC
    $CMMB
    Financials

    Live finance-specific insights

    View All

    Apyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026

    CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81

    2/25/26 9:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

    Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), at the 49th Macula Soc

    2/23/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

    First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% of subjects in the AXPAXLI™ arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to aflibercept (2 mg) arm 65.9% of subjects treated with AXPAXLI maintained vision at Week 52, a 21.1% risk difference (p<0.0001), compared to aflibercept (2 mg) arm Rescue-free rates in the AXPAXLI arm were 80.6%, 74.7%, and 68.8% at Weeks 24, 36, and 52 55.9% of subjects treated with AXPAXLI maintained CSFT within 30 μm from baseline at Week 36, a 17.1% risk difference (nominal p=0.0

    2/17/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $APYX
    $ATPC
    $CMMB
    Leadership Updates

    Live Leadership Updates

    View All

    Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

    Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success

    1/21/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $APYX
    $ATPC
    $CMMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Chemomab Therapeutics Ltd.

    SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    11/29/24 3:04:59 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Chemomab Therapeutics Ltd.

    SC 13G - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    11/21/24 10:59:28 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $APYX
    $ATPC
    $CMMB
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care